

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

**SUPPLEMENTAL ANNOUNCEMENT
IN RELATION TO THE ANNUAL REPORT OF THE COMPANY FOR THE YEAR
ENDED 31 DECEMBER 2015**

The announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”, together with its subsidiaries, the “**Group**”) further to its annual report for the year ended 31 December 2015 (the “**2015 Annual Report**”).

References are made to the joint announcements of Company and Fosun International Holdings Limited dated 26 April 2013, 28 May 2013, 26 August 2014 and 23 April 2015, the announcement of the Company dated 29 June 2015 (the “**Announcements**”) and the circular of the Company dated 12 May 2015 (the “**Circular**”), in relation to, among other things, the acquisition by Sisram Medical Ltd. (“**Sisram Medical**”) of the equity interest in Alma Lasers Ltd. (“**Alma Lasers**”) and the adoption of Sisram Medical plan and the proposed grant of Sisram options (the “**Sisram Medical Plan**”). Unless otherwise specified, capitalized terms used herein shall have the same meaning as ascribed to them in the Announcements and the Circular.

The Board would like to provide the following additional information to the 2015 Annual Report regarding the Sisram Medical Plan as contemplated under Rule 17.09 of the Hong Kong Listing Rules and certain of which has previously been included in the Announcements and Circular:

Sisram Medical Plan

On 29 June 2015, the shareholders of the Company approved the adoption of the Sisram Medical Plan. The purpose of Sisram Medical Plan is to enhance the management participation in Alam Lasers, which is important that they would be offered an opportunity to obtain ownership interest in Sisram Medical and to enjoy the results of Sisram Medical attained through their efforts and contributions. The persons eligible for participation in the Sisram Medical Plan shall include any Sisram Employees and/or Non-Sisram Employees of Sisram Medical or any of its Associates, and the basis for their eligibility shall be determined by the Sisram Board based on such Sisram Participant's contribution or potential contribution to the development and growth of Sisram Medical.

The total number of Sisram Shares which may be issued upon exercise of all options to be granted under the Sisram Medical Plan is 106,500 Sisram Shares, representing approximately 14.49% of the issued share capital at the date of the 2015 Annual Report. Subject to adjustment from time to time pursuant to the terms of the Sisram Medical Plan, a maximum of 100,000 Sisram Shares, representing approximately 13.61% of Sisram Medical's issue share capital as at the date of the 2015 Annual Report, shall be available for issuance under the Sisram Medical Plan.

The maximum number of Sisram Shares issued and to be issued upon the exercise of the Awards granted under the Sisram Medical Plan and any other share option schemes of Sisram Medical to the participation in the Sisram Medical Plan (including both exercised and outstanding Awards), in any twelve-month period up to the date of grant shall not exceed 1% of the number of Sisram Shares in issue as at the date of grant unless (i) the issue of a circular by the Company and Fosun International containing such particulars as may be required by the Hong Kong Listing Rules from time to time is dispatched to their respective shareholders; (ii) the shareholders of the Company and Fosun International approve the grant of the Awards in excess of the 1% limit referred to in the Sisram Medical Plan; and (iii) the relevant Sisram Participant and its associates shall abstain from voting.

Unless determined otherwise in the relevant Award Agreement, with respect to any, some or all Sisram Options, each Sisram Option shall vest and become exercisable over a four-year period from its Date of Grant, such that one-sixteenth of such Sisram Shares shall vest at the end of each three-month period, on each anniversary of the Date of Grant, commencing on the first anniversary, provided that the Sisram Participant remains continuously employed by or in the service of Sisram Medical or its Affiliate during the relevant year.

As at the date of this announcement, no Sisram Option has been granted under the Sisram Medical Plan. The Sisram Medical Plan shall terminate at the end of ten years from its day of adoption, unless terminated earlier in accordance with the terms of the Sisram Medical Plan. The Purchase Price of each Sisram Share subject to a Sisram Option shall be determined by the Sisram Board or the Committee at its sole and absolute discretion in accordance with Applicable Law, and shall not be less than the Fair Market Value of Sisram Shares on the date of grant. If such authority is delegated by the Sisram Board to the Committee in compliance with the then effective Applicable Law, it shall be subject to any guidelines as may be determined by the Sisram Board from time to time. No consideration is payable to Sisram Medical upon acceptance of the Sisram Option in accordance with the terms of the Sisram Medical Plan.

The Board confirmed that the above additional information does not affect other information contained in the 2015 Annual Report.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
Chairman

Shanghai, People's Republic of China

26 April 2016

As at the date of this announcement, the executive Directors are Mr. Chen Qiyu and Mr. Yao Fang; the non-executive Directors are Mr. Guo Guangchang, Mr. Wang Qunbin, Ms. Kang Lan and Mr. John Changzheng Ma; and the independent non-executive Directors are Dr. Zhang Weijiong, Mr. Cao Huimin, Mr. Jiang Xian and Dr. Wong Tin Yau Kelvin.

* *for identification purposes only*